Common Contracts

Contract

May 5th, 2020

• Filed
  May 5th, 2020

<DOCUMENT> <TYPE>EX-10.5 <SEQUENCE>9 <FILENAME>y32191exv10w5.txt <DESCRIPTION>EX-10.5: EXCLUSIVE LICENSE AGREEMENT <TEXT> <PAGE> Exhibit 10.5 EXCLUSIVE LICENSE AGREEMENT between NOVO NORDISK A/S, Novo Alle, 2880 Bagsvaerd, Denmark - Danish company identification number CVR 24 25 67 90 (hereinafter referred to as "NOVO NORDISK") and AMICUS THERAPEUTICS, Inc., 675 U.S. Highway One, North Brunswick, NJ 08902, USA (hereinafter referred to as "AMICUS THERAPEUTICS"). Hereinafter individually referred to as "Party" and collectively as "Parties"; WITNESSETH: WHEREAS, AMICUS THERAPEUTICS is involved in development of small molecule enzyme chaperones for treatment of genetic and metabolic diseases; WHEREAS, NOVO NORDISK is the owner of certain Intellectual Property Rights relating to glycogen phosphorylase inhibitors, its use and in particular patent rights relating to a specific glycogen phosphorylase inhibitor NN4201; WHEREAS, NOVO NORDISK wishes to license to AMICUS THERAPEUTICS such Intellec